While biopharma executives, investors and deal-makers are busy presenting at the J.P. Morgan Healthcare Conference in San Francisco, global political attention is fixating on a deal signed thousands of miles away.
Trade, IP And Oncology Deals: What You Need To Know About China And JPM20
China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.
More from China
More from Focus On Asia
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
• By
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.